“This quarter, Celldex (CLDX) continued to demonstrate our leadership in the field of mast cell biology, presenting exciting data across our pipeline programs,” said Anthony Marucci, co-founder, president and CEO of Celldex. “Barzolvolimab is the first in the field to demonstrate clinical benefit in a large, randomized, placebo-controlled study of cold urticaria and symptomatic dermographism, and we were also pleased to report additional endpoints from our Phase 2 CSU study and promising data from CDX-622, the first stem cell factor neutralizing bispecific antibody to be studied in humans, which we designed to also target TSLP.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex appoints Lawver as Chief Commercial Officer
- Celldex’s Promising Phase II Trial Results Justify Buy Rating
- Celldex’s Promising Phase 2 Trial Results and Strong Financial Position Support Buy Rating
- Celldex’s Barzolvolimab Shows Promising Phase 2 Results, Justifying Buy Rating
- Celldex announces additional data on barzolvolimab